Reported Earnings • May 20
Full year 2026 earnings released: EPS: JP¥501 (vs JP¥401 in FY 2025) Full year 2026 results: EPS: JP¥501 (up from JP¥401 in FY 2025). Revenue: JP¥811.6b (flat on FY 2025). Net income: JP¥31.0b (up 22% from FY 2025). Profit margin: 3.8% (up from 3.1% in FY 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Hiromi Miyake was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Mar 18
Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026 Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026 Aankondiging • Dec 02
Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026 Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026 Aankondiging • Nov 10
Kaneka Expands Global Reach with i-ED COIL Launch in Europe Kaneka Corporation has begun sales of its i-ED COIL, a brain aneurysm embolization coil in Europe as of October. The product obtained EC certification under an EU Medical Device Regulation in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. The i-ED COIL provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. Looking ahead, company aim to strengthen the global reach of products such as i-ED COIL and achieve sales of JPY 300 billion by 2030 in the Health Care Solution Unit including these medical businesses. Aankondiging • Sep 01
Kaneka Corporation to Report Q2, 2026 Results on Nov 12, 2025 Kaneka Corporation announced that they will report Q2, 2026 results on Nov 12, 2025 Aankondiging • Jun 13
Kaneka Corporation to Report Q1, 2026 Results on Aug 08, 2025 Kaneka Corporation announced that they will report Q1, 2026 results on Aug 08, 2025 Aankondiging • May 16
Kaneka Corporation (TSE:4118) announces an Equity Buyback for 3,000,000 shares, representing 4.77% for ¥12,000 million. Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 3,000,000 shares, representing 4.77% of the outstanding shares for ¥12,000 million. The purpose of the program is to improve shareholder value and implement flexible capital policies in response to changes in the business environment. The program will run until March 29, 2026. As of April 30, 2025, the company had 62,934,292 shares outstanding and 3,065,708 shares in treasury. Aankondiging • May 14
Kaneka Corporation, Annual General Meeting, Jun 27, 2025 Kaneka Corporation, Annual General Meeting, Jun 27, 2025. Aankondiging • Mar 21
Kaneka Corporation to Report Fiscal Year 2025 Results on May 14, 2025 Kaneka Corporation announced that they will report fiscal year 2025 results on May 14, 2025 Aankondiging • Jan 09
Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd. Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus device for aneurysm treatment currently under development. We aim to achieve sales of over ¥20 billion by 2030.
Kaneka Corporation (TSE:4118) completed the acquisition of 96.80% stake in EndoStream Medical Ltd on December 23, 2024. Aankondiging • Dec 21
Kaneka Corporation to Report Q3, 2025 Results on Feb 13, 2025 Kaneka Corporation announced that they will report Q3, 2025 results on Feb 13, 2025 Reported Earnings • Nov 15
Second quarter 2025 earnings released: EPS: JP¥49.73 (vs JP¥71.73 in 2Q 2024) Second quarter 2025 results: EPS: JP¥49.73 (down from JP¥71.73 in 2Q 2024). Revenue: JP¥197.6b (up 5.4% from 2Q 2024). Net income: JP¥3.13b (down 33% from 2Q 2024). Profit margin: 1.6% (down from 2.5% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 15% per year. Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €19.80, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 11x in the Chemicals industry in Germany. Total loss to shareholders of 32% over the past three years. Upcoming Dividend • Sep 20
Upcoming dividend of JP¥60.00 per share Eligible shareholders must have bought the stock before 27 September 2024. Payment date: 05 December 2024. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.0%). Aankondiging • Sep 18
Kaneka Corporation to Report Q2, 2025 Results on Nov 12, 2024 Kaneka Corporation announced that they will report Q2, 2025 results on Nov 12, 2024 Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €20.80, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 32% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €16.18 per share. Aankondiging • Jun 18
Kaneka Corporation to Report Q1, 2025 Results on Aug 08, 2024 Kaneka Corporation announced that they will report Q1, 2025 results on Aug 08, 2024 Reported Earnings • May 19
Full year 2024 earnings released: EPS: JP¥358 (vs JP¥350 in FY 2023) Full year 2024 results: EPS: JP¥358 (up from JP¥350 in FY 2023). Revenue: JP¥762.3b (flat on FY 2023). Net income: JP¥23.2b (flat on FY 2023). Profit margin: 3.0% (in line with FY 2023). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 11% per year. Aankondiging • May 16
Kaneka Corporation, Annual General Meeting, Jun 27, 2024 Kaneka Corporation, Annual General Meeting, Jun 27, 2024. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥55.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 12 June 2024. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (4.8%). Aankondiging • Mar 13
Kaneka Corporation to Report Fiscal Year 2024 Results on May 14, 2024 Kaneka Corporation announced that they will report fiscal year 2024 results on May 14, 2024 Reported Earnings • Feb 11
Third quarter 2024 earnings released: EPS: JP¥69.95 (vs JP¥34.88 in 3Q 2023) Third quarter 2024 results: EPS: JP¥69.95 (up from JP¥34.88 in 3Q 2023). Revenue: JP¥194.6b (up 4.3% from 3Q 2023). Net income: JP¥4.54b (up 96% from 3Q 2023). Profit margin: 2.3% (up from 1.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings. Buying Opportunity • Jan 18
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 5.2%. The fair value is estimated to be €27.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 7.0%. Revenue is forecast to grow by 8.9% in 2 years. Earnings is forecast to grow by 92% in the next 2 years. Aankondiging • Nov 30
Kaneka Corporation to Report Q3, 2024 Results on Feb 08, 2024 Kaneka Corporation announced that they will report Q3, 2024 results on Feb 08, 2024 Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: JP¥71.73 (vs JP¥91.80 in 2Q 2023) Second quarter 2024 results: EPS: JP¥71.73 (down from JP¥91.80 in 2Q 2023). Revenue: JP¥187.4b (flat on 2Q 2023). Net income: JP¥4.66b (down 23% from 2Q 2023). Profit margin: 2.5% (down from 3.2% in 2Q 2023). Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 21
Upcoming dividend of JP¥55.00 per share at 2.7% yield Eligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 43% but the company is not cash flow positive. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (5.9%). Aankondiging • Sep 13
Kaneka Corporation to Report Q2, 2024 Results on Nov 09, 2023 Kaneka Corporation announced that they will report Q2, 2024 results on Nov 09, 2023 New Risk • Aug 10
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.2% Last year net profit margin: 4.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.2% net profit margin). Reported Earnings • Aug 10
First quarter 2024 earnings released: EPS: JP¥65.35 (vs JP¥161 in 1Q 2023) First quarter 2024 results: EPS: JP¥65.35 (down from JP¥161 in 1Q 2023). Revenue: JP¥182.7b (down 5.2% from 1Q 2023). Net income: JP¥4.24b (down 60% from 1Q 2023). Profit margin: 2.3% (down from 5.5% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Aankondiging • Jun 15
Kaneka Corporation to Report Q1, 2024 Results on Aug 09, 2023 Kaneka Corporation announced that they will report Q1, 2024 results on Aug 09, 2023 Reported Earnings • May 18
Full year 2023 earnings released: EPS: JP¥350 (vs JP¥406 in FY 2022) Full year 2023 results: EPS: JP¥350 (down from JP¥406 in FY 2022). Revenue: JP¥755.8b (up 9.3% from FY 2022). Net income: JP¥23.0b (down 13% from FY 2022). Profit margin: 3.0% (down from 3.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Aankondiging • May 17
Kaneka Corporation, Annual General Meeting, Jun 29, 2023 Kaneka Corporation, Annual General Meeting, Jun 29, 2023. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥55.00 per share at 3.3% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 13 June 2023. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.7%). Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: JP¥34.87 (vs JP¥111 in 3Q 2022) Third quarter 2023 results: EPS: JP¥34.87 (down from JP¥111 in 3Q 2022). Revenue: JP¥186.5b (up 4.5% from 3Q 2022). Net income: JP¥2.32b (down 68% from 3Q 2022). Profit margin: 1.2% (down from 4.1% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Aankondiging • Dec 17
Kaneka Corporation to Report Q3, 2023 Results on Feb 08, 2023 Kaneka Corporation announced that they will report Q3, 2023 results on Feb 08, 2023 Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 4 independent directors (8 non-independent directors). Independent Director Yuko Sasakawa was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 11
Second quarter 2023 earnings released: EPS: JP¥91.80 (vs JP¥107 in 2Q 2022) Second quarter 2023 results: EPS: JP¥91.80 (down from JP¥107 in 2Q 2022). Revenue: JP¥187.9b (up 13% from 2Q 2022). Net income: JP¥6.05b (down 14% from 2Q 2022). Profit margin: 3.2% (down from 4.2% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥55.00 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (6.1%). Reported Earnings • Aug 12
First quarter 2023 earnings released: EPS: JP¥161 (vs JP¥119 in 1Q 2022) First quarter 2023 results: EPS: JP¥161 (up from JP¥119 in 1Q 2022). Revenue: JP¥192.7b (up 17% from 1Q 2022). Net income: JP¥10.5b (up 36% from 1Q 2022). Profit margin: 5.5% (up from 4.7% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.2%, compared to a 2.9% growth forecast for the industry in Germany. Aankondiging • Jun 11
Kaneka Corporation to Report Q1, 2023 Results on Aug 10, 2022 Kaneka Corporation announced that they will report Q1, 2023 results on Aug 10, 2022 Reported Earnings • May 15
Full year 2022 earnings released: EPS: JP¥406 (vs JP¥243 in FY 2021) Full year 2022 results: EPS: JP¥406 (up from JP¥243 in FY 2021). Revenue: JP¥691.5b (up 20% from FY 2021). Net income: JP¥26.5b (up 67% from FY 2021). Profit margin: 3.8% (up from 2.7% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.3%, compared to a 6.4% growth forecast for the industry in Germany. Aankondiging • May 14
Kaneka Corporation, Annual General Meeting, Jun 29, 2022 Kaneka Corporation, Annual General Meeting, Jun 29, 2022. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Managing Executive Officer & Director Katsunobu Doro was the last director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Buying Opportunity • Apr 21
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be €31.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 9.3%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings is also forecast to grow by 6.8% per annum over the same time period. Aankondiging • Apr 13
Kaneka Launches New PCR Test Kit for Identifying the COVID-19 Omicron (BA.1) and "Stealth" Omicron (BA.2) Variants Kaneka Corporation released KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta) ver.2”, a real-time PCR test kit capable of simultaneously detecting the Omicron (BA.1), "Stealth" Omicron (BA.2), and Delta variants of COVID-19. This test kit uses a proprietary reagent developed using Kaneka's molecular testing-related technologies to detect the presence of three variants with a single PCR test. This is expected to help reduce the burden placed by testing and to assist with selecting the best suitable drugs and treatment approaches for each variant in clinical settings. Kaneka has already released the KANEKA Direct RT-PCR Kit SARS-CoV-2, an in-vitro diagnostic reagent that uses Kaneka's original sample processing technology to produce test results in less than an hour, KANEKA RT-PCR Kit “SARS-CoV-2 (L452R/E484Q/E484K/N501Y)”, which can detect four variants simultaneously, and KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta)” which can detect the Delta and Omicron variants of COVID-19. These Kaneka products are being used at major sporting events and for pre-travel PCR testing, as well as in medical facilities and testing centers. These products make it possible to quickly test large numbers of samples. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥60.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (4.7%). Reported Earnings • Feb 09
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2022 results: EPS: JP¥111 (up from JP¥110 in 3Q 2021). Revenue: JP¥178.4b (up 15% from 3Q 2021). Net income: JP¥7.26b (up 1.0% from 3Q 2021). Profit margin: 4.1% (down from 4.6% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.9%. Over the next year, revenue is forecast to stay flat compared to a 6.0% growth forecast for the industry in Germany. Reported Earnings • Nov 10
Second quarter 2022 earnings released: EPS JP¥107 (vs JP¥31.26 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥166.2b (up 19% from 2Q 2021). Net income: JP¥7.01b (up 244% from 2Q 2021). Profit margin: 4.2% (up from 1.5% in 2Q 2021). The increase in margin was driven by higher revenue. Upcoming Dividend • Sep 22
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 29 September 2021. Payment date: 07 December 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (3.7%). Reported Earnings • Aug 14
First quarter 2022 earnings released: EPS JP¥119 (vs JP¥6.70 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥164.1b (up 30% from 1Q 2021). Net income: JP¥7.76b (up JP¥7.32b from 1Q 2021). Profit margin: 4.7% (up from 0.3% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Reported Earnings • May 16
Full year 2021 earnings released: EPS JP¥243 (vs JP¥215 in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥577.4b (down 4.0% from FY 2020). Net income: JP¥15.8b (up 13% from FY 2020). Profit margin: 2.7% (up from 2.3% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Mar 24
Upcoming dividend of JP¥50.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 11 June 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (3.6%). Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improved over the past week After last week's 17% share price gain to JP¥39.40, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 19x in the Chemicals industry in Germany. Total returns to shareholders of 8.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €24.18 per share. Aankondiging • Mar 11
Kaneka Corporation to Report Fiscal Year 2021 Results on May 13, 2021 Kaneka Corporation announced that they will report fiscal year 2021 results on May 13, 2021 Is New 90 Day High Low • Feb 16
New 90-day high: €32.60 The company is up 29% from its price of €25.20 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.16 per share. Reported Earnings • Feb 11
Third quarter 2021 earnings released: EPS JP¥110 (vs JP¥48.85 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥154.8b (up 1.4% from 3Q 2020). Net income: JP¥7.18b (up 125% from 3Q 2020). Profit margin: 4.6% (up from 2.1% in 3Q 2020). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Analyst Estimate Surprise Post Earnings • Feb 11
Revenue beats expectations Revenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 3.3%, compared to a 5.1% growth forecast for the Chemicals industry in Germany. Is New 90 Day High Low • Jan 26
New 90-day high: €30.00 The company is up 26% from its price of €23.80 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.58 per share. Is New 90 Day High Low • Jan 08
New 90-day high: €29.20 The company is up 16% from its price of €25.20 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.44 per share. Aankondiging • Dec 17
Kaneka Corporation to Report Q3, 2021 Results on Feb 09, 2021 Kaneka Corporation announced that they will report Q3, 2021 results on Feb 09, 2021 Is New 90 Day High Low • Dec 17
New 90-day high: €28.40 The company is up 19% from its price of €23.80 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.62 per share. Analyst Estimate Surprise Post Earnings • Nov 14
Revenue beats expectations Revenue exceeded analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 1.1%, compared to a 3.6% growth forecast for the Chemicals industry in Germany. Is New 90 Day High Low • Nov 12
New 90-day high: €25.80 The company is up 22% from its price of €21.20 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.41 per share. Reported Earnings • Nov 11
Second quarter 2021 earnings released: EPS JP¥31.26 The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥140.1b (down 7.3% from 2Q 2020). Net income: JP¥2.04b (down 20% from 2Q 2020). Profit margin: 1.5% (down from 1.7% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 12
New 90-day high: €25.60 The company is up 21% from its price of €21.20 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.76 per share. Is New 90 Day High Low • Sep 18
New 90-day high: €24.80 The company is up 8.0% from its price of €23.00 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.11 per share. Aankondiging • Sep 13
Kaneka Corporation to Report Q2, 2021 Results on Nov 10, 2020 Kaneka Corporation announced that they will report Q2, 2021 results on Nov 10, 2020 Aankondiging • Jun 28
Kaneka Corporation to Report Q1, 2021 Results on Aug 12, 2020 Kaneka Corporation announced that they will report Q1, 2021 results on Aug 12, 2020 
